Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
100
peopleWording
Definitive
How definitive the wording is.Announced details
Applicable field (uses covered by this announcement)
IR and information provision to investors
Launch date26 September 2026 (scheduled; seminar date)
Relationship between the counterparty and the company
Oncolys BioPharma Inc.4588
Relationship with the Company
Organizer of the IR seminar
Counterparty株式会社ストックボイス
Location (as indicated in this announcement)
TKP Sapporo Station Conference Center, Hall 3D (Bellvue Office Sapporo 3F, 7-9-2 Kita 7-jo Nishi, Kita-ku, Sapporo, Hokkaido)
Capacity: 100 people
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Counterparty | 株式会社ストックボイス |
| Relationship with the Company | Organizer of the IR seminar |
| Launch date | 26 September 2026 (scheduled; seminar date) |
| Applicable area | IR and information provision to investors |
| Location | TKP Sapporo Station Conference Center, Hall 3D (Bellvue Office Sapporo 3F, 7-9-2 Kita 7-jo Nishi, Kita-ku, Sapporo, Hokkaido) |
| Location scale | Capacity: 100 people |
Items this document does not state (12)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is an announcement of speaking at an IR seminar explaining the company and its business activities. No further specific explanation is provided regarding the reason for the speaking engagement.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.